Prevalence of oral glucocorticoid usage in the United States: A general population perspective
Article first published online: 30 JAN 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 2, pages 294–298, February 2013
How to Cite
Overman, R. A., Yeh, J.-Y. and Deal, C. L. (2013), Prevalence of oral glucocorticoid usage in the United States: A general population perspective. Arthritis Care Res, 65: 294–298. doi: 10.1002/acr.21796
- Issue published online: 30 JAN 2013
- Article first published online: 30 JAN 2013
- Accepted manuscript online: 17 JUL 2012 12:46PM EST
- Manuscript Accepted: 27 JUN 2012
- Manuscript Received: 8 FEB 2012
There is little information on oral glucocorticoid use in the general US population. Previously, there have been published estimates of glucocorticoid use in countries outside of the US. This study aimed to estimate the prevalence of glucocorticoid use, duration of use, and concomitant use of antiosteoporosis pharmaceuticals in the US population age ≥20 years.
Data from 5 cycles (1999–2008) of the National Health and Nutrition Examination Survey (NHANES) were used to provide nationally representative weighted estimates. Oral glucocorticoids and concomitant use of antiosteoporosis pharmaceuticals (bisphosphonates, calcitonin, calcium, hormone replacement therapies, teriparatide, and vitamin D) were analyzed.
There were 356 NHANES respondents ages ≥20 years who reported use of an oral glucocorticoid in the combined cycles between 1999 and 2008. The weighted prevalence of oral glucocorticoid use was 1.2% (95% confidence interval [95% CI] 1.1–1.4) from 1999–2008, corresponding to 2,513,259 persons in the US. The mean duration of oral glucocorticoid use was 1,605.7 days (95% CI 1,261.2–1,950.1), and 28.8% (95% CI 22.2–35.4) of oral glucocorticoid users reported use for ≥5 years. Concomitant use of a bisphosphonate was reported by 8.6% (95% CI 5.1–11.7) of oral glucocorticoid users, and 37.9% (95% CI 31.7–44.0) reported usage of any antiosteoporosis pharmaceutical.
Based on NHANES data from 1999–2008, it is estimated that the prevalence of glucocorticoid use in the US is 1.2%, with a long duration of use and infrequent use of antiosteoporotic medications compared to other estimates.